 |
인쇄하기
취소
|
Velcade, Novel Anticancer Treatment, Now Available Under NHI Coverage
Janssen Korea announced this week that the company has completed the registration of Velcade (bortezomib) injection, a novel anticancer treatment, to the National Health Insurance (NHI) list of approved medications, and is now available in the domestic market starting February.
Regarded as the first in a new class of anticancer agents known as proteasome inhibitors, Velcade was approved b...
Regarded as the first in a new class of anticancer agents known as proteasome inhibitors, Velcade was approved b...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.